ACADIA Pharmaceuticals 2015 Annual Report

ACADIA Pharmaceuticals' 2015 annual report highlights the FDA approval of NUPLAZID (pimavanserin) for treating hallucinations and delusions associated with Parkinson's disease psychosis. The company outlines its pipeline development plans, including Phase II trials for Alzheimer's disease psychosis and schizophrenia, and discusses the significant clinical and caregiver burden of Parkinson's disease psychosis.